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Abstract
Background: Although resistance to isoniazid (INH) is the most common form of drug resistance
seen among Mycobacterium tuberculosis isolates, there have been few studies on the efficacy and
optimal duration of treatment for patients with INH-resistant tuberculosis (TB).
Methods: We evaluated retrospectively the treatment outcomes of 39 patients who were treated
for INH-resistant pulmonary TB. The treatment regimens consisted of a 12-month regimen of
rifampin (RIF) and ethambutol (EMB), with pyrazinamide (PZA) given during the first 2 months
(2HREZ/10RE) (n = 21), a 9-month regimen of RIF and EMB with PZA during the first 2 months
(2HREZ/7RE) (n = 5), and a 6-month regimen of RIF, EMB, and PZA (2HREZ/4REZ) (n = 13). After
drug susceptibility testing confirmed the INH-resistance of the isolated M. tuberculosis strains, INH
was discontinued for all the patients.
Results: Among the 39 patients, treatment was successfully completed by 36 patients (92%).
However, treatment failure occurred, and acquired resistance to other first-line drugs, such as RIF,
developed in three patients (8%). Cavitary and bilateral extensive lesions were commonly found in
the chest radiographs of the patients who exhibited treatment failure.
Conclusion: These findings underline the seriousness of concerns regarding treatment failure and
the development of multidrug-resistant TB in patients with INH-resistant TB following treatment
with recommended regimens.
Background
Recent global surveys have revealed that drug-resistant
tuberculosis (TB) exists in virtually every location exam-
ined [1-3]. Among drug-resistant M. tuberculosis isolates,
resistance to isoniazid (INH) was the most commonly
observed type [1].
Previous studies have suggested that standard, 6-month,
four-drug regimens may be effective in the treatment of
INH-resistant TB [4]. However, the guidelines for the
treatment of TB published recently by the American Tho-
racic Society and British Thoracic Society have stated that
it would be more prudent either to administer pyrazina-
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mide (PZA) continuously throughout the 6-month treat-
ment period or to prolong the duration of treatment [5-7].
It is very surprising that the efficacies of these recom-
mended regimens have not been evaluated fully. Recently,
we encountered a case of pulmonary TB with acquired
multidrug resistance (MDR) during a 12-month treatment
of INH-resistant TB with RIF and EMB, with PZA adminis-
tered during the first 2 months [8]. The aims of the present
study were to evaluate retrospectively the treatment out-
comes for INH-resistant TB with the various regimens rec-
ommended in the previous guidelines and published
literature.
Methods
We searched the database of all notified cases of pulmo-
nary TB diagnosed and treated in our institutions between
July 2001 and June 2005. Permission was obtained from
the Institutional Review Board to review and publish ret-
rospectively the patients' records.
The drug susceptibilities of the M. tuberculosis isolates were
determined by the absolute concentration method, using
Lowenstein-Jensen medium at the Korean Institute of
Tuberculosis [9]. The drugs and their critical concentra-
tions for resistance were as follows: INH, 0.2 µg·mL-1;
RIF, 40 µg·mL-1; SM, 4 µg·mL-1; and EMB, 2 µg·mL-1.
PZA susceptibility was determined by the pyrazinamidase
test [10].
INH resistance was defined as resistance to INH alone or
INH plus streptomycin (SM). In total, 53 patients with
INH-resistant pulmonary TB were identified and their
medical records were analyzed retrospectively. We
excluded patients who were lost to follow-up (n = 6) and
those who had been transferred to other institutions, usu-
ally to their referring institutions before completion of
treatment (n = 7). We also excluded one patient who died
of gastrointestinal bleeding during treatment for TB.
A patient was designated as being cured if conversion
from positive to negative sputum culture was achieved
after the start of treatment and the patient remained cul-
ture-negative throughout the period of treatment. Sputum
culture conversion was defined as the time in months
from the time treatment was started to the time at which
the first negative sputum culture was obtained. Treatment
failure was defined in bacteriologic terms for patients
who, while on treatment, continued to be, or reverted to
being, smear-positive and/or culture-positive 5 months or
more after commencing treatment [11,12]. "Treatment
completed" was the definition given to those patients who
had completed treatment but who did not meet the crite-
ria to be classified as instances of cure or failure. In this
study, both cure and treatment completed were regarded
as treatment successes.
Results
Baseline characteristics
The baseline clinical characteristics of the 39 patients with
INH-resistant pulmonary TB are listed in Table 1.
Twenty-three (59%) patients were smear-positive and cul-
ture-positive, and 16 (41%) patients were smear-negative
and culture-positive. Cavitary lesions were identified in
the chest radiographs of 15 (38%) patients. Bilateral
lesions were found in 17 (44%) patients, and extensive
lesions, which were defined as the involvement of two or
more lobes in the same lung, were detected in 8 (21%)
patients.
Table 1: Baseline characteristics of 39 patients with isoniazid-resistant pulmonary tuberculosis
Patient characteristics Treatment Success (n = 36) Treatment failure (n = 3)
Sex Male 24 (67%) 2 (67%)
Female 12 (33%) 1 (33%)
Median age in years (range) 41 (24–71) 55 (55–72)
Comorbidity Diabetes mellitus 2 2
Malignancy 4 0
Chronic liver disease 2 1
Chronic pulmonary disease 2 1
Others 5 0
Smear-positive 20 (56%) 3 (100%)
Type of resistance Isoniazid 31 (86%) 3 (100%)
Isoniazid and streptomycin 5 (14%) 0
History of treatment New 23 (64%) 2 (67%)
Relapse 10 (28%) 1 (33%)
Treatment after default 3 (8%) 0
Radiographic findings Cavitary lesion 13 (36%) 2 (67%)
Bilateral lesion 15 (42%) 2 (67%)
Extensive lesion 6 (17%) 2 (67%)BMC Infectious Diseases 2008, 8:6 http://www.biomedcentral.com/1471-2334/8/6
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Treatment regimens
All of the patients initially received daily therapy that
comprised INH, RIF, EMB, and PZA, which was strongly
recommended by the National Tuberculosis Program [13-
15]. After drug susceptibility testing confirmed the INH-
resistance of the isolated M. tuberculosis strains, INH treat-
ment was discontinued for all the patients. For 13 (33%)
patients in whom INH-resistance was identified before
the end of the 2-month initial phase of treatment, PZA
was included in the treatment regimen for the entire 6
months (2HREZ/4REZ). In 25 (64%) patients, drug sus-
ceptibility test results were available during the continua-
tion phase of treatment. In these 25 patients, RIF and EMB
were continued for 12 months in 21 (54%) patients
(2HREZ/10RE) and for 9 months in 5 (13%) patients
(2HREZ/7RE). All of the regimens were administered
daily for the full duration of therapy.
Treatment compliance was assessed by comparing the
number of administered treatment doses to the number of
treatment doses scheduled each month. There were no
consistently missing doses corresponding to ≥ 10 days of
monthly scheduled doses of medication for all the
patients. Trained nurses checked the adherence of patients
and called patients who did not show up for their
monthly appointment. All the patients completed the
treatment regimen without modification.
Treatment outcomes
Treatment was successfully completed in 36 patients
(92%), and 35 (90%) were cured. Table 2 shows the
elapsed times for sputum culture conversion for these
patients with INH-resistant pulmonary TB. The majority
(30/36, 83%) of the patients converted from culture-pos-
itive to culture-negative status after 1 month of treatment.
However, treatment failure occurred in three patients
(8%). In two patients, progression to resistance to INH
and RIF (MDR) was identified during the treatment of
2HREZ/10RE regimen. Sputum conversion of smears and
cultures was initially achieved after 3 and 4 months of
treatment in these patients. However, the sputum culture
returned to positivity and the isolated organism was
found to be resistant to INH and RIF after 9 and 10
months of treatment. In one patient, sputum smears and
cultures remained persistently positive after 5 months of
treatment of 2HREZ/4REZ and resistance to both INH and
PZA developed. Initial sputum AFB smear was positive in
all these patients with treatment failure. Two patients had
cavitary lesion and two patients had bilateral lesion on
their initial chest radiographs.
Discussion
A review of 12 controlled trials conducted in Africa, Hong
Kong, and Singapore had revealed that the standard 6-
month, four-drug regimens may be effective in the treat-
ment of INH-resistant TB [4]. However, that review [4]
also stated that, "the proportion of relapse in regimens
containing RIF throughout was approximately twice as
high in patients with initial resistance to INH as in those
with sensitive strains." In addition, one large-scale multi-
national cohort study revealed that treatment failure is
higher among patients with any INH resistance other than
MDR in both new cases and retreatment cases who have
Table 2: Treatment outcome and time from start of treatment to conversion of sputum culture among 39 patients with isoniazid-
resistant pulmonary tuberculosis
Treatment regimen Number of patients Treatment success Treatment failure
Sputum conversion from positive to negative culture at
1 month 2 months 3 months Follow-up sputum sample not available*
2HREZ/10RE Smear-positive (n = 12) 7 1 1 1 2
Smear-negative (n = 9) 8 1 - - -
2HREZ/4REZ Smear-positive (n = 9) 6 1 1 - 1
Smear-negative (n = 4) 4 - - - -
2HREZ/7RE Smear-positive (n = 2) 2 - - - -
Smear-negative (n = 3) 3 - - - -
Total (n = 39) 30 3 2 1 3
* One patient, who was diagnosed as having culture-positive pulmonary tuberculosis based on bronchoscopic examination, could not expectorate 
sputum after the initiation of treatment. This patient could not expectorate sputum after the initiation of treatment. The radiographic abnormality 
disappeared completely after the treatment, and this patient was classified as a treatment success.
2HREZ/10RE: 12-month regimen of rifampin (RIF) and ethambutol (EMB), with pyrazinamide (PZA) during the first 2 months; 2HREZ/4REZ: 6-
month regimen of RIF, EMB, and PZA; 2HREZ/7RE: 9-month regimen of RIF and EMB, with PZA during the first 2 months. After drug susceptibility 
testing confirmed the INH-resistance of the isolated M. tuberculosis strains, INH treatment was discontinued for all the patients.BMC Infectious Diseases 2008, 8:6 http://www.biomedcentral.com/1471-2334/8/6
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received short-course chemotherapy with INH, RIF, PZA,
and either EMB or SM [16]. Another study also found that
INH resistance was strongly associated with treatment fail-
ure during standardized short-course chemotherapy for
TB, and many patients involving treatment failures
acquired new MDR [17].
The American Thoracic Society and British Thoracic Soci-
ety have recommended several treatment regimens for the
treatment of INH-resistant TB, which included 6REZ,
2REZ/10RE, and 12RE [5-7]. In addition, some studies
have suggested that a 9-month regimen of 2REZ(S)/7RE
may be valuable for the treatment of INH-resistant TB
[18,19]. However, in spite of the presence of the different
treatment regimens listed above, the optimal treatment
regimen and duration remain unclear, as the efficacies of
these regimens have not been fully evaluated in a prospec-
tive randomized fashion. Indeed, many physicians treat
INH-resistant TB patients with widely varying regimens in
daily clinical practice [20].
In the present study, the treatment success rate was 92%
and treatment failure occurred in three cases (8%). The
overall success rates of 90% (19/21) for 2HREZ/10RE,
92% (12/13) for 2HREZ/4REZ, and 100% (5/5) for
2HREZ/7RE. One case of treatment failure developed dur-
ing treatment with the 2HREZ/4REZ regimen and two
cases of treatment failure developed during treatment
with 2HREZ/10RE. Importantly, the acquisition of addi-
tional resistance to other first-line drugs occurred in each
of these cases. The cavitary and bilateral extensive lesions
seen in the chest radiographs of these patients were com-
monly associated with treatment failure, and the sputum
smears of these patients were positive.
Interestingly, the recently revised treatment guidelines by
the American Thoracic Society and the World Health
Organization state that fluoroquinolones may augment
the 6REZ regimen for the treatment of patients with INH-
resistant pulmonary TB who have more extensive disease
[6,21]. During the study period, however, the flouroqui-
nolones were not used in the treatment of INH-resistant
pulmonary TB in our institutions.
The present study has many important limitations that are
generally inherent to retrospective analyses. The effective-
ness of various regimens for the treatment of INH-resist-
ant TB cannot be deduced from our study, since the
numbers of patients who received the various regimens
are insufficient for the purpose of comparison. More
importantly, the assignment of the treatment regimens
was not random. In addition, our institutions did not per-
form directly observed therapy (DOT). Then, the possibil-
ity of poor compliance of treatment regimen could not be
completely excluded.
Conclusion
Our report underlines the seriousness of concerns regard-
ing treatment failure and the development of MDR-TB in
patients with INH-resistant TB following treatment with
recommended regimens.
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